SMMT supply chain intelligence for Summit Therapeutics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Summit Therapeutics Inc. (SMMT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AKESO | AKESO | 92% | Pursuant to the terms of the License Agreement, Summit has final decision-making authority with respect to all of its commercialization activities including, but not limited to, commercial strategy, … |
| AKESO-INC | AKESO-INC | 92% | Since in-licensing ivonescimab, from Akeso Inc. (Akeso, HKEX Code: 9926.HK) in January 2023, over 4,000 patients have been treated with ivonescimab in clinical studies globally, and over 70,000 patie… |
| GSK | GSK plc | 90% | In January 2026, we announced a clinical collaboration with GSK plc (GSK) to evaluate ivonescimab in combination with GSK's novel B7-H3, risvutatug rezetecan, in multiple solid tumors. |
| GSK | GSK plc | 90% | Reciprocal relationship from GSK graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from GSK graph: Reciprocal relationship from SMMT graph: In January 2026, we announced a clini… |
| REVOLUTION-MEDICINES-INC | REVOLUTION-MEDICINES-INC | 90% | In June 2025, we announced a clinical collaboration with Revolution Medicines, Inc. (RevMed) to evaluate ivonescimab in combination with three RAS(ON) inhibitors, including the multi-selective 3 inhi… |
| GORTEC | GORTEC | 85% | In February 2026, we announced a clinical collaboration with GORTEC, a European Head and Neck Oncology and Radiotherapy Group based in France, to evaluate ivonescimab monotherapy and ivonescimab in c… |
| BNTX | BioNTech SE | 72% | commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia… |
| BNTX | BioNTech SE | 72% | Reciprocal relationship from BNTX graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions … |
| CBIO | Crescent Biopharma, Inc. | 72% | Reciprocal relationship from CBIO graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from CBIO graph: ave no significant experience as a company in initiating, conducting, or com… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regio… |
| CELG-RI | CELG-RI | 72% | commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia… |
| JNJ | Johnson & Johnson | 72% | commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from JNJ grap… |
| MRK | Merck & Co., Inc. | 72% | commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (… |
| PLSE | Pulse Biosciences, Inc. | 72% | Reciprocal relationship from PLSE graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from PLSE graph: on an ongoing basis. Although we cannot predict the ultimate impact of any s… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BNTX | BioNTech SE | 72% | commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia… |
| BNTX | BioNTech SE | 72% | Reciprocal relationship from BNTX graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from BNTX g… |
| CELG-RI | CELG-RI | 72% | commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regio… |
| GSK | GSK plc | 72% | Reciprocal relationship from GSK graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from GSK graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from GSK grap… |
| GSK | GSK plc | 72% | se Agreement Pursuant to the License Agreement with Akeso, the Company received the rights to develop and commercialize ivonescimab in the Licensed Territory. Akeso retained development and commercia… |
| JNJ | Johnson & Johnson | 72% | commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (… |
| MRK | Merck & Co., Inc. | 72% | commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from MRK graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from MRK grap… |
| J-P-MORGAN-SECURITIES-LLC | J-P-MORGAN-SECURITIES-LLC | 62% | se Agreement Pursuant to the License Agreement with Akeso, the Company received the rights to develop and commercialize ivonescimab in the Licensed Territory. Akeso retained development and commercia… |
| RADIOTHERAPY-GROUP | RADIOTHERAPY-GROUP | 62% | se Agreement Pursuant to the License Agreement with Akeso, the Company received the rights to develop and commercialize ivonescimab in the Licensed Territory. Akeso retained development and commercia… |
| REVOLUTION-MEDICINES-INC | REVOLUTION-MEDICINES-INC | 62% | se Agreement Pursuant to the License Agreement with Akeso, the Company received the rights to develop and commercialize ivonescimab in the Licensed Territory. Akeso retained development and commercia… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SMMT-DEBT-12608 | Warrants outstanding: 3358732 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| SMMT-DEBT | Debt stack $20.0M | 90% | Market cache reports total debt of $20.0M. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CELG-RI | BRISTOL MYERS SQUIBB CO | 100.00 | 1 | ['customer', 'supplier'] |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| BSX | Boston Scientific Corporation | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 1 | ['supplier'] |
| BDRX | Biodexa Pharmaceuticals Plc | 100.00 | 2 | |
| SNNUF | Smith & Nephew plc | 100.00 | 2 |